Johnson & Johnson Raises 2025 Guidance
Image Source: J&J By Brian Nelson, CFA On July 16, Johnson & Johnson (JNJ) reported better than expected second quarter results with both revenue and non-GAAP earnings per share exceeding the consensus forecast. The healthcare giant reported adjusted operational sales growth of 3% in the quarter (2.4% growth in Innovative Medicine and 4.1% growth in MedTech) and adjusted earnings per share of $2.77, down modestly on a year-over-year basis. Free cash flow was ~$6.2 billion in the quarter, also down from $7.5 billion that it registered in the second quarter of last year. Management had the following to say about the results: Today’s strong results reflect the depth and strength of Johnson & Johnson’s uniquely diversified business operating across both … Read more